Therapeutic Advances in Oncology

Liu, Jinsha; Pandya, Priyanka; Afshar, Sepideh

doi:10.3390/ijms22042008

Cited by 36 publications

(25 citation statements)

References 161 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neratinib has also been reported to be effective in treating early HER-2+ breast cancers as shown by the results from the ExteNET trial [85]. Furthermore, tucatinib, yet another selective HER2 inhibitor, was also approved in 2020 for breast cancer patients who developed brain metastases [86,87].…”

Section: Drugs Known To Target Cd82 Tyrosine Kinase Inhibitors (Tkis)mentioning

confidence: 99%

Targeting CD82/KAI1 for Precision Therapeutics in Surmounting Metastatic Potential in Breast Cancer

Viera

Yip

Shen

et al. 2021

Cancers

View full text Add to dashboard Cite

Metastasis is the main cause of mortality in breast cancer patients. There is an unmet need to develop therapies that can impede metastatic spread. Precision oncology has shown great promise for the treatment of cancers, as the therapeutic approach is tailored to a specific group of patients who are likely to benefit from the treatment, rather than the traditional approach of “one size fits all”. CD82, also known as KAI1, a glycoprotein belonging to the tetraspanin family and an established metastasis suppressor, could potentially be exploited to hinder metastases in breast cancer. This review explores the prospect of targeting CD82 as an innovative therapeutic approach in precision medicine for breast cancer patients, with the goal of preventing cancer progression and metastasis. Such an approach would entail the selection of a subset of breast cancer patients with low levels of CD82, and instituting an appropriate treatment scheme tailored towards restoring the levels of CD82 in this group of patients. Proposed precision treatment regimens include current modalities of treating breast cancer, in combination with either clinically approved drugs that could restore the levels of CD82, CD82 peptide mimics or non-coding RNA-based therapeutics.

show abstract

Section: Drugs Known To Target Cd82 Tyrosine Kinase Inhibitors (Tkis)mentioning

confidence: 99%

Targeting CD82/KAI1 for Precision Therapeutics in Surmounting Metastatic Potential in Breast Cancer

Viera

Yip

Shen

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Currently, Bcl-2 blockers are considered as modern promising drugs to overcome drug resistance. Venetoclax, a Bcl-2 inhibitor, is already available to treat chronic lymphocytic leukemia in patients with specific chromosomal abnormalities [ 99 ]. There is strong evidence that progesterone regulates bcl-2 expression in cancer and non-cancer cells.…”

Section: Progestins As Chemosensitizers Possible Targetsmentioning

confidence: 99%

Progestins as Anticancer Drugs and Chemosensitizers, New Targets and Applications

Федотчева

Shimanovsky

2021

Pharmaceutics

View full text Add to dashboard Cite

Progesterone and its synthetic analogues, progestins, participate in the regulation of cell differentiation, proliferation and cell cycle progression. Progestins are usually applied for contraception, maintenance of pregnancy, and hormone replacement therapy. Recently, their effectiveness in the treatment of hormone-sensitive tumors was revealed. According to current data, the anticancer activity of progestins is mainly mediated by their cytotoxic and chemosensitizing influence on different cancer cells. In connection with the detection of previously unknown targets of the progestin action, which include the membrane-associated progesterone receptor (PR), non-specific transporters related to the multidrug resistance (MDR) and mitochondrial permeability transition pore (MPTP), and checkpoints of different signaling pathways, new aspects of their application have emerged. It is likely that the favorable influence of progestins is predominantly associated with the modulation of expression and activity of MDR-related proteins,the inhibition of survival signaling pathways, especially TGF-β and Wnt/β-catenin pathways, which activate the proliferation and promote MDR in cancer cells, and the facilitation of mitochondrial-dependent apoptosis. Biological effects of progestins are mediated by the inhibition of these signaling pathways, as well as the direct interaction with the nucleotide-binding domain of ABC-transporters and mitochondrial adenylate translocase as an MPTP component. In these ways, progestins can restore the proliferative balance, the ability for apoptosis, and chemosensitivity to drugs, which is especially important for hormone-dependent tumors associated with estrogen stress, epithelial-to-mesenchymal transition, and drug resistance.

show abstract

“…Contemporary medicine is oriented at application of target methods of cancer therapy, including molecular, cellular, gene therapies and preventive measures, antibody-drug conjugates, nanoparticles of biopolymers, metals, polymeric micelles and other nanoparticles (Liu et al, 2021). Antibody-drug conjugates are a separate class of immune-chemotherapy preparations.…”

Section: Perspectives Of Using Cytotoxic Compounds Of Marine Origin In Oncology and New Biomedical Technologiesmentioning

confidence: 99%

“…Substances isolated from marine organisms (or their synthe-tic analogues) are considered to be promising beneficial loads for future ADC: hemiasterlin, taltobulin, cemadotin, cryptoficine, discodermolide (Ponziani et al, 2020). New knowledge of the carcenogenesis processes and successes of gene engineering led to development of bispecific antibodies (bsAbs) that have an effect on two targets of carcenogenesis -alter the processes of cellular signal transmission and suspend further growth and metastasis of tumours (Liu et al, 2021). Unlike regular chemotherapeutic dugs, antibody-drug conjugates are a promising and most dynamically developing class of drugs, and have broad therapeutic range due to effective and specific transport of drug to antigen-expressing tumour cells (Mukherjee et al, 2019;Khongorzul et al, 2020).…”

Section: Perspectives Of Using Cytotoxic Compounds Of Marine Origin In Oncology and New Biomedical Technologiesmentioning

confidence: 99%

Anti-tumour drugs of marine origin currently at various stages of clinical trials (review)

Bocharova

Копытина

Slynko

2021

Regul. Mech. Biosyst.

View full text Add to dashboard Cite

Oncological diseases for a long time have remained one of the most significant health problems of modern society, which causes great losses in its labour and vital potential. Contemporary oncology still faces unsolved issues as insufficient efficacy of treatment of progressing and metastatic cancer, chemoresistance, and side-effects of the traditional therapy which lead to disabilities among or death of a high number of patients. Development of new anti-tumour preparations with a broad range of pharmaceutical properties and low toxicity is becoming increasingly relevant every year. The objective of the study was to provide a review of the recent data about anti-tumour preparations of marine origin currently being at various phases of clinical trials in order to present the biological value of marine organisms – producers of cytotoxic compounds, and the perspectives of their use in modern biomedical technologies. Unlike the synthetic oncological preparations, natural compounds are safer, have broader range of cytotoxic activity, can inhibit the processes of tumour development and metastasis, and at the same time have effects on several etiopathogenic links of carcinogenesis. Currently, practical oncology uses 12 anti-tumour preparations of marine origin (Fludarabine, Cytarabine, Midostaurin, Nelarabine, Eribulin mesylate, Brentuximab vedotin, Trabectedin, Plitidepsin, Enfortumab vedotin, Polatuzumab vedotin, Belantamab mafodotin, Lurbinectedin), 27 substances are at different stages of clinical trials. Contemporary approaches to the treatment of oncological diseases are based on targeted methods such as immune and genetic therapies, antibody-drug conjugates, nanoparticles of biopolymers, and metals. All those methods employ bioactive compounds of marine origin. Numerous literature data from recent years indicate heightened attention to the marine pharmacology and the high potential of marine organisms for the biomedicinal and pharmaceutic industries.

show abstract

Therapeutic Advances in Oncology

Cited by 36 publications

References 161 publications

Targeting CD82/KAI1 for Precision Therapeutics in Surmounting Metastatic Potential in Breast Cancer

Targeting CD82/KAI1 for Precision Therapeutics in Surmounting Metastatic Potential in Breast Cancer

Progestins as Anticancer Drugs and Chemosensitizers, New Targets and Applications

Anti-tumour drugs of marine origin currently at various stages of clinical trials (review)

Contact Info

Product

Resources

About